^
Association details:
Biomarker:BCL2 overexpression
Cancer:Lung Cancer
Drug:Tagrisso (osimertinib) (EGFR inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Title:

Overcoming the acquired resistance to gefitinib in lung cancer brain metastasis in vitro and in vivo

Published date:
08/28/2021
Excerpt:
AZD9291 was also shown to overcome acquired resistance to gefitinib in PC-9-Br in MTT assays (0.23 ± 0.031 µM at 48 h and 0.03 ± 0.008 µM at 72 h)....In conclusion, our study demonstrated gefitinib + ABT263/ABT199, afatinib, and AZD9291 have clinical potential to treat LCBM.
DOI:
10.1007/s00204-021-03147-4